M2 Pharma - Policy and Regulations

Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

19 July 2019 - - German drugmaker Boehringer Ingelheim and South Korea-based Bridge Biotherapeutics Inc. are entering into a new collaboration and license agreement with the goal of developing Br...

Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors

19 July 2019 - - Irish small molecule therapeutics developer Inflection Biosciences (Inflection) and Singapore-based AUM Biosciences, a company focused on the development of innovative and affordable ...

Dan Retires from Sesen Bio Board of Directors

19 July 2019 - - Leslie L. Dan has retired from US-based fusion protein therapeutics developer Sesen Bio's (NASDAQ: SESN) board of directors, the company said.
With the retirement of ...

Cortexyme's Approach to Addressing a Key Underlying Cause of Alzheimer's Detailed at Alzheimer's Association International Conference 2019

19 July 2019 - - US-based biopharmaceutical company Cortexyme, Inc. (NASDAQ: CRTX) has presented clinical data that supports its ongoing work to pioneer a novel, disease-modifying therapeutic approach...

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga (regorafenib) and Opdivo (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer

19 July 2019 - - German drugmaker Bayer, US-based Bristol-Myers Squibb Company (NYSE: BMY) and Japan-based Ono Pharmaceutical Co., Ltd. have entered into a clinical collaboration agreement to eva...

Pharmazz Inc begins Phase III trial of PMZ-1620 in cerebral ischemic stroke patients

19 July 2019 - Critical care medicine company Pharmazz Inc said on Thursday that it has received clearance to launch a prospective, multicentric, randomized, double-blind, parallel, phase III clinical...